Onyvax Issued Broad US Patent For Prostate
London, UK – 3 March, 2004: Onyvax Limited, the biotechnology
company developing novel cancer therapies, today announced that
it has been issued a broad patent (U.S. Patent No. 6,699,483)
that includes specific composition of matter claims relating
to the Company's proprietary prostate cancer vaccine programme.
The patent covers the combined use of three human prostate tumour
cell lines in a vaccine treatment designed to stimulate the immune
system to fight prostate cancer, and significantly strengthens
the Company’s intellectual property position.
Dr. Anthony Walker, CEO of Onyvax Ltd, said: "We are pleased
to have been issued this broad patent which strengthens our intellectual
property position around our Cell Vaccine technologies. The ownership
of particular cell lines will remain the cornerstone of our proprietary
position, but this patent provides additional protection and
enhances our competitive stance going forward”.
Cell Vaccines are designed to induce a powerful immune response
against a broad range of prostate cancer-associated antigens
without the severe side effects often associated with conventional
cancer therapies, such as radio or chemotherapy. In the UK, around
21,000 men are diagnosed with prostate cancer per year and about
9,500 die of the disease annually. The number of cases in the
UK has risen by 25% in the last five years. According to the
American Cancer Society, prostate cancer is the most common cancer
among men in the US, with an estimated 220,900 new cases diagnosed
each year. It is the second leading cause of cancer death in
American men, with about 28,900 deaths per year, exceeded only
by lung cancer.
Onyvax is developing a number of cancer vaccines including Onyvax-P,
a Cell Vaccine for the treatment of prostate cancer. Interim
data from a Phase II clinical trial has shown that treatment
with Onyvax-P slows down the rate of PSA release in men with
hormone resistant prostate cancer and may also slow down the
rate of disease progression. Onyvax expects to release final
data from this trial later this year and is preparing to initiate
phase III pivotal clinical trials within the next year.
For further information, please contact:
Dr Anthony Walker / Rob Johnson
+44 (0)20 8682 9119
Francetta Carr / Lucy Briggs
+44 (0)20 7831 3113
Notes to Editors:
Onyvax Ltd is a biotechnology company developing novel cancer
therapies that harness the selective power of the immune system
to seek and destroy tumour cells.
Founded in 1997, Onyvax has three product candidates in clinical
trials designed for the treatment of prostate and other cancers.
Onyvax’s lead products are based on combinations of inactivated
cell lines that induce immune responses to a broad spectrum of
tumour targets. Onyvax-P, a Cell Vaccine for prostate cancer,
is due to enter Phase III clinical trials within 12 months. For
each cancer type, Onyvax generates banks of proprietary cell
lines representative of different stages of the disease. The
vaccines are manufactured in bulk under standardised conditions.
Onyvax is committed to the commercialisation of new therapies
that significantly prolong survival while maintaining a high
quality of life for cancer patients. The Company is based in
London and has collaborations with leading institutions in Europe
and the US.
Further information on Onyvax can be found at www.onyvax.com